BSA‐CuS Nanoparticles for Photothermal Therapy of Diabetic Wound Infection In Vivo

Abstract Diabetic vascular stenosis and multi‐drug resistance limit the efficacy of traditional antibiotic therapy to the diabetic wound infection, so developing advanced therapy is highly desired. Photothermal therapy (PTT) is a novel noninvasive technique and enables transferring near‐infrared (NIR) light energy into heat to kill bacteria pathogens directly using PTT agents. Among various PTT agents, bovine serum albumin stabilized‐CuS (BSA‐CuS) nanoparticles are emerging as an ideal PTT agent with the advantages of simple preparation, low cost, low toxicity, good biocompatibility, high photothermal conversion efficiency. However, no one has applied this high‐performance PTT nanoagent in the treatment of diabetic wound infection in vivo. Herein, we present PTT for diabetic wound infection in vivo using BSA‐CuS nanoparticles. The prepared CuS nanoparticles exhibited low cytotoxicity and in vivo toxicity, excellent water solubility and high photothermal performance. Most of the bacteria in vitro were destroyed after the treatment of BSA‐CuS nanoparticles and laser irradiation. Furthermore, the infected wounds of diabetic mice treated with CuS nanoparticles‐based PTT healed faster than the control group with negligible systemic damage. The proposed PTT using BSA‐CuS nanoparticles opens up a new way for the treatment of diabetic wound infection in vivo, and shows great potential in clinical translation for antibacterial treatment against various diseases.